XLIFE-SCIENCES-AG
8.1.2021 09:10:26 CET | Business Wire | Press release
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.
According to the concluded licensing agreement with Baliopharm AG, Xlife Sciences AG will receive 10% of all future licensing income up to a maximum of 300 million euros. This applies to the company's entire line of active ingredients. Xlife Sciences AG thus participates directly in the future success and innovative strength of a leading biotech company in the field of antibody therapies with this transaction.
On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG |
Klausstrasse 19 |
|
8008 Zürich |
|
Switzerland |
|
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: |
1159182 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005126/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Unveils 2026 Customer Award Winners at Kinexions in Las Vegas4.6.2026 13:00:00 CEST | Press release
Global supply chain leaders recognized for delivering bold innovation, agility, and measurable impact Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the winners of its 2026 Customer Awards. Now in their eighth year, these awards were celebrated live at Kinexions North America, the flagship premiere global conference hosted by Kinaxis, bringing together supply chain leaders from around the world. The annual awards spotlight organizations and individuals who are redefining what’s possible in modern supply chains. The winners are driving innovation, responding with agility, and delivering real business results with the Kinaxis Maestro™ platform. The awards recognized seven leading companies including Reckitt, General Motors, Lupin, Jabil, and Cardinal Health among the full list of winners. Additionally, Praveen Vasudevan (Bio-Rad Laboratories) received the champion award for their industry contributions. “Kinexions is where the
STARTEEPO Invest Increases Stake in Xerox to More Than 6% Ahead of Q2 2026 Earnings4.6.2026 13:00:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to more than 6% of the Company’s outstanding common stock, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. Following the transaction, STARTEEPO beneficially owns approximately 8.0 million Xerox common shares and holds options on an additional 140,000 shares. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s third-largest shareholder. “We continue to view Xerox as a high-conviction investment and one of the largest positions in our portfolio,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. “Our conviction has increased as we continue to analyze the Company’s publicly available disclosures, strategic initiatives, and transformation efforts.” Increasing Conviction Ahead
Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology4.6.2026 10:10:00 CEST | Press release
Reply [EXM, STAR: REY] and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. The initiative brings together Reply’s expertise in building frontier generative models grounded in enterprise knowledge with the IEO’s clinical expertise and data assets to develop models tailored to highly complex oncology settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604488955/en/ Reply and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. As a first step, the IEO’s clinical teams and Information Systems department are working with a multidisciplinary Reply team with deep expertise in healthcare and LLM specialisation to define and prioritise the use cases that will guide development, while also map
UK AI Minister Kanishka Narayan Joins The AI Summit London as 10th Anniversary Agenda Expands Across Enterprise AI, Innovation and Policy4.6.2026 10:00:00 CEST | Press release
London Tech Week's flagship AI event will feature 300 speakers, live AI demonstrations, startup pitch competitions, executive training and the National AI Awards The AI Summit London today revealed the full agenda for its highly anticipated 10th anniversary edition, delivering its most expansive and future-focused programme to date. Taking place 10–11 June at Tobacco Dock as the headline AI event of London Tech Week 2026, the Summit expects more than 5,000 attendees, 300 speakers, 100+ sponsors and exhibitors, and a special executive presentation from Kanishka Narayan, Minister for AI and Online Safety, Department for Science, Innovation and Technology, across two days dedicated to the commercial realities and transformative potential of artificial intelligence. The 10th anniversary has been designed to move the conversation beyond experimentation and into enterprise-wide execution. New in 2026, the programme introduces The AI Impact Arena, delivering focused briefings and live demos,
Corona Launches 2026 Beach 100 Guide, Invites The World To Explore The Outdoors This Summer4.6.2026 10:00:00 CEST | Press release
Ahead of World Oceans Day, the global beach authority returns with a list of new locations, over 300,000 Tripadvisor experiences, and dedicated beach grants as part of its “This is Living” platform Corona, the world’s most valuable beer brand1, today announced the return of its annual global beach guide, the 2026 Corona Beach 100, ahead of World Oceans Day on June 8. The highly anticipated second edition spotlights 100 breathtaking and varied ocean-front destinations around the world while celebrating the natural ecosystems and local communities that help bring them to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604412899/en/ 2026 Corona Beach 100 - Legzira Beach, Morocco Connected to Corona’s “This Is Living” platform, which invites consumers to step outside and live life to the fullest this summer, the 2026 guide features 27 new beaches, hundreds of localized Tripadvisor travel experiences inspired by the world
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom